Press Releases

March 7, 2022 Lupin signs on Mary Kom for its Women’s Cardiovascular Health Awareness Initiative, Shakti

March 3, 2022 Lupin Receives Approval from U.S. FDA for Efinaconazole Topical Solution

March 1, 2022 Lupin Launches Sevelamer Hydrochloride Tablets in the United States

February 23, 2022 Lupin Announces Executive Leadership Change, Dr. Fabrice Egros to assume Corporate Development responsibilities as President, Corporate Development & Growth Markets

February 17, 2022 Lupin Announces FDA Approval of Supplemental New Drug Application for SOLOSEC® (secnidazole) in Adolescents for both the Treatment of Bacterial Vaginosis in Females and Trichomoniasis

February 9, 2022 Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla®

February 8, 2022 Lupin Receives Approval from U.S. FDA for Arformoterol Tartrate Inhalation Solution15 mcg (base)/2 ml

February 3, 2022 Lupin Quarter 3 FY2022 Results

February 1, 2022 Lupin and Axantia Enter into a License, Supply and Technology Sharing Agreement for Pegfilgrastim in the Middle East and North Africa